Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Compelling evidence supports the existence of a profound immune dysregulation in patients with chronic myeloproliferative neoplasms (MPN). Increased Arginase-1 expression has been described in MPN patients and in solid cancers. This increase contributes to an immunosuppressive tumor microenvironment in MPN patients because of L-arginine depletion by Arginase-1-expressing regulatory cells and cancer cells, which subsequently limits the activation of circulating effector cells. In the present study, we demonstrate that Arginase-1-derived peptides are recognized by T cells among peripheral mononuclear blood cells from MPN patients. We characterized the Arginase-1-specific T cells as being CD4+ and found that the magnitude of response to the Arginase-1 peptides depends on disease stage. Activation of Arginase-1-specific T cells by vaccination could be an attractive novel immunotherapeutic approach to targeting malignant and suppressive cells in MPN patients in combination with other immunotherapeutics.
Originalsprog | Engelsk |
---|---|
Artikelnummer | e1468957 |
Tidsskrift | OncoImmunology |
Vol/bind | 7 |
Udgave nummer | 9 |
Antal sider | 8 |
ISSN | 2162-4011 |
DOI | |
Status | Udgivet - 2018 |
Links
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140593/pdf/koni-07-09-1468957.pdf
Forlagets udgivne version
ID: 208875526